Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?

Ruby Haviv 1,2*, Veronica Moshe 1, Fabrizio De Benedetti 3, Giusi Prencipe 3, Noa Rabinowicz 1 and Yosef Uziel 1,2

Abstract

Background: Fibrodysplasia ossificans progressiva (FOP) is the most catastrophic form of heterotopic ossification, due to ongoing intracellular signaling through the bone morphogenic protein pathway. The paroxysmal appearance of inflammatory lumps and elevated inflammatory markers during flares, suggest that FOP is an auto-inflammatory disease. Based on evidence, demonstrating a role for interleukin-1β (IL-1β) in other forms of heterotopic ossification, we hypothesized that treating FOP patients with anti-IL-1 agents could help lower the rate of FOP paroxysms and/or limit the symptoms and residual lesions.

Case presentation: A 13.5-year-old Arab boy was diagnosed with FOP. Treatment with anti-inflammatory drugs did not change the disease course. New lumps appeared in a rate of approximately one every 8 days. Treatment with the anti-IL-1 agents anakinra and canakinumab resulted in significantly lower rate of paroxysms (every 22–25 days, of which almost all involved only 2 existing lumps), as well as shorter duration. High levels of IL-1β were found in the patient’s plasma samples, collected during a paroxysm that appeared 8 weeks after the last canakinumab dose. In contrast, IL-1β plasma levels were undetectable in the previous three plasma samples, obtained while he was treated with anti-IL-1 agents.

Conclusions: Our data demonstrate the efficacy of anti-IL-1 agents in the treatment of a patient with FOP. Results showing the marked increase in IL-1β plasma levels during a paroxysm support a role for IL-1β in the pathogenesis of FOP and further provide the rationale for the use of anti-IL-1 agents in FOP treatment.

Keywords: Fibrodysplasia ossificans progressiva, FOP, Heterotopic ossification, Interleukin, IL-1, IL-1β, Anakinra, Canakinumab

Background

Fibrodysplasia ossificans progressiva (FOP) is the most catastrophic form of heterotopic ossification (HO). This rare genetic disease (1 in 1,360,000–2,000,000) [1] is caused by mutations in the ACVR1/ALK2 gene, encoding the type I bone morphogenetic protein (BMP) receptor. R206H missense gain-of-function is the most frequent mutation, and is located at the end of the highly conserved glycine-serine region of the cytoplasmic domain of the receptor [2], adjacent to the protein kinase domain. Gain of function mutations in ACVR1 cause ongoing intra-cellular signaling of the BMP pathway (through phosphorylation of Smad1/5/8), which alters cellular fate and induces undifferentiated mesenchymal cells to form cartilage, and later on leads to complete ossification of muscle, as well as subcutaneous and other mesenchymal tissues.

The heterotopic bone continues to expand and even remodels itself through an Activin A-dependent process [3, 4]. Activin A (as other Activins) is also known to have an inhibitory role, as it competes with BMP in binding to its receptor, but does not induce downstream phosphorylation of the transcription factors Smad1/5/8 [4].

Clinically, painful, soft tissue swellings usually start appearing during the first decade of life, and 95 percent of FOP patients experience their first “paroxysm” before the age of 15 years. However, a typical, bilateral deformity of the hallux can be noted at birth in about 80% of patients [5].
Currently, there is no established, effective treatment for FOP. Of the few anti-inflammatory therapies reported, such as anti-leukotrienes, non-steroidal anti-inflammatory drugs, mast-cell stabilizers [6] and sirolimus [7], none had a major effect on disease progression. When lumps appear, high dose corticosteroids (either oral prednisone 2 mg/kg/day or intravenous methylprednisolone pulse), along with a bisphosphonate infusion, are used [6]. A few specific drugs are “in the pipeline” (Regenron’s garetosmab, an anti-Activin A antibody and Clementia’s palovarotene, a retinoic acid receptor-gamma agonist) [7], but these are still unavailable for prescription. Anti-tumor necrosis factor α agents were not successful in treating the disease (personal communication).

Average life expectancy is around 45 years. By the third decade of life, most FOP patients are wheelchair-bound [6]. A main cause of morbidity is related to ankylosis of the temporomandibular joints and the most common cause of mortality is thoracic insufficiency syndrome [5, 7–9].

The recurrent paroxysmal appearance of inflammatory lumps (tender, localized swellings, with erythematous skin superficially, which partially react to anti-inflammatory agents), accompanied by elevated inflammatory markers during flares, may suggest that FOP is an auto-inflammatory disease. The episodic formation of bone, often following a trivial injury, suggests that innate immune-related triggers induce tissue transformation through the BMP pathway [10]. Moreover, interleukin-1β (IL-1β), a well-known mediator of the innate immune system, has been linked to HO and mineralization in human bone marrow-derived mesenchymal stem cell cultures [11–13]. We hypothesized that treating a FOP patient with anti-IL-1 agents could help ameliorate the progression of this devastating disease, by slowing the rate of paroxysms, and/or limiting the symptoms and residual lesions. We report our experience.

Case presentation
A 13.5-year-old, Muslim Arab boy was diagnosed clinically with FOP. Diagnosis was confirmed after genetic testing (the typical R206H mutation in the ACVR1/ALK2 gene was found). When first examined, he already had asymmetrical shoulder positioning and limited rotation of the neck, spine and left hip. In addition, bony mass formations were palpated on his right waist, medial to his right scapula and left paravertebral region. He also had non-rigid, non-tender, warm swellings within the sternocleidomastoid muscles, bilaterally. His halluces were abnormally short and wide. He had undergone an osteotomy when he was 7-years-old, to straighten their congenital valgus position (Fig. 1).

Laboratory tests results showed mildly elevated inflammatory markers, including CRP (approximately 3 mg/dL, normal values 0–0.5 mg/dL), mild leukocytosis with moderate neutrophilia and mild microcytic anemia.

Total body CT revealed generalized osteopenia, “chondrocalcinosis” of the left hip joint capsule, thickened fascia and infiltrated fat and anteverision of the femoral head (Fig. 2). Coarse lumbar paravertebral calcifications within muscles were also seen (Fig. 3). MRI of the cervical spine revealed non-homogenously edematous sternocleidomastoid muscles and thickening of the strap muscles and the muscles around his right scapula, thickening of the submental fascia and infiltration of subcutaneous fat (Fig. 4).

Treatment with high-dose corticosteroids, pamidronate infusions, and daily celecoxib and monteleukast did not change the course of the disease, and new lumps continued to appear at a rate of approximately one new lump every 8 days. Anakinra treatment was initiated (100 mg/day; patient’s weight was over 100 kg). After marked improvement was noted over a 2-month period, he was treated with canakinumab 300 mg, every 4 weeks, for 5 more months. Markedly lower rate and duration of
paroxysms was documented (Fig. 5 clearly shows a reduc-
tion from 3 to 4 to 1–2 flares per month, one every 22–
25 days, of which almost all involved only 2 existing lumps – see more below), with shorter courses of methylprednis-
alone during flares (mostly 1–2 doses, instead of 3). More-
over, lumps were markedly smaller and softer.

Canakinumab treatment was then withheld for 8
weeks. During this time, lumps appeared more fre-
quently. He experienced one flare during the 36 days
following the fifth canakinumab dose, but at least 4
more between day 37 and day 54, with the appearance
of new lumps on his torso and neck, and especially a
large lump below his left scapula. Canakinumab treat-
ment was then reinitiated.

Cytokine measurements
Plasma IL-1β, IL-6 and IL-18 levels were measured in
samples collected from the patient, and from controls,
by enzyme-linked immunosorbent assay, using the Hu-
man IL-1β /IL-1F2 Quantikine High Sensitivity ELISA
Kit (R&D System), the Human IL-6 Quantikine High
Sensitivity ELISA Kit (R&D System) and the Human IL-
18 Elisa kit (MBL corporation), according to the manu-
facturer’s instructions.

Notably, while unmeasurable levels of IL-1β (< 0.125
pg/ml) were found in the three plasma samples obtained
from the patient during treatment with anakinra or
canakinumab, high levels of IL-1β (up to 21.52 pg/ml,
about 90-fold higher compared to average levels mea-
sured in healthy controls) were found in the patient’s
plasma samples collected during the flare (Fig. 6). In
contrast, IL-18 and IL-6 plasma levels, measured before,
during and after withholding treatment, were compar-
able or slightly higher than those observed in healthy
controls (Fig. 7a, b).

The patient has been treated with canakinumab ap-
proximately 3.5 mg/kg/month for more than 16 months,
with a relatively low flare rate of approximately one
every 25 days (Fig. 5). The lumps involved in almost all
of these flares are the same: at the left scapular base and
within the right sternocleidomastoid muscle. We docu-
mented a decrease in the size of the left scapular lump
from 4.5 × 4.5 cm to 3.5 × 2.5 cm within 2 weeks after
subcutaneous injection of canakinumab, without the
addition of corticosteroids (Fig. 8).
**Discussion**

To the best of our knowledge, this is the first time anti-IL-1 agents have been shown to ameliorate the natural progression of FOP. In addition, plasma IL-1β, IL-18 and IL-6 levels in longitudinal samples, collected from a FOP patient, show that IL-1β levels, but not IL-18 and IL-6 levels, increased significantly during flares.

Activins and BMPs are expressed by innate immune system cells during inflammation [4]. The linkage between FOP, heterotopic bone formation and inflammation was observed long ago, and macrophages derived from FOP patients have been found in a pro-inflammatory state, with increased expression of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) [10, 14]. Elevated IL-3, IL-12p70 (the active heterodimer form), IL-6, and other inflammatory factors have been linked to HO, related to combat wounds and high-energy trauma [15, 16].

Although IL-1β has been studied minimally in the context of FOP, it has been linked to HO through several studies. Mahy and Urist reported that recombinant IL-1β enhanced a process of BMP-induced HO, and this effect was completely eliminated by administration of antibodies against IL-1 [11]. Ferreira and colleagues reported that IL-1β and TNF-α strongly induced mineralization in 8 of 10 cultures of human bone marrow-derived mesenchymal stem cells. The IL-1β were mediated via the MAPK, rather than the NF-κB signaling pathway, despite suppression of osteoblastic differentiation. This study suggested that suppressed expression of the ectonucleotide pyrophosphatase/phosphodiesterase-1 gene (ENPP1) could be one of the causes, leading to suppression of extracellular pyrophosphate (PPi) levels, which is linked to HO [12].

Ezura et al. investigated the effects of IL-1β on the mineralization of human and mouse bone marrow mesenchymal cells, by focusing on the alternative extracellular calcification mechanism through regulation of extracellular levels of inorganic phosphate (Pi), PPi, and adenosine. Characteristic suppression of the osteoblastic marker genes by IL-1β during a 20-day osteogenic culture, and reduced expression of the important transporter genes, ANKH (human Ank homologue) and ENT1 (SLC29A1), were observed. ANKH and ENT1 are the plasma membrane transporters for the byproducts of nucleotide metabolism (Pi and adenosine, respectively) and are involved in the regulatory system for HO. Extracellular Pi and PPi are well-known byproducts of nucleotide metabolism and are recognized to be very important for HO pathogenesis [13].

---

**Fig. 5** Number of FOP flares per month, based on documentation held by the patient’s family, the patient’s pediatrician and the rheumatology unit. Note the marked change in the mean number of flares, just after the initiation of anti-IL-1 treatment (between the dashed blue lines), and a temporary elevation in flare frequency while canakinumab was withheld.
High levels of IL-1β (up to 21.52 pg/ml) were found in the patient’s plasma (13–14/11/2018) during the appearance of a large new lump below his left scapula, after canakinumab treatment was withheld for 8 weeks. In contrast, undetectable (ND) levels of IL-1β (< 0.125 pg/ml) were observed in the previous three plasma samples obtained during treatment with anakinra (03/05/2018) or canakinumab (05/06/2018), and without temporal proximity to a new lump (01/02/2018).

IL-18 (a) and IL-6 (b) plasma levels, measured before, during and after withholding treatment, were comparable or slightly higher than those observed in healthy controls.
Using principal component analysis, Barruet and colleagues reported no significant differences in IL-1α and IL-1β levels, secreted by lipopolysaccharide (LPS)-stimulated monocytes of either control or FOP patients (during a flare), and significantly increased IL-1 receptor antagonist levels in FOP monocytes, after LPS stimulation [14]. Reviewing their report, it is important to mention that blood samples from only 4 FOP patients were used for this analysis, and higher IL-1α and IL-1β levels were measured in two of them. All 4 patients were using anti-inflammatory drugs (principally NSAIDs), one had still been using a corticosteroid 4 days before the blood sample was taken, and the other two patients were using corticosteroid 10 days before blood samples were taken.

In summary, there is growing evidence that the nature of HO in general and FOP specifically, is inflammatory, and that anti-inflammatory drugs may ameliorate this process. IL-1 has a role in this process, along with other mediators, but there are insufficient data to determine how important it is in comparison to other inflammatory cascades and mediators. Moreover, a laboratory model to link IL-1β and FOP is lacking.

In this case, a clear beneficial effect of anti-IL1 agents has been shown: a marked decrease in flare frequency, almost no appearance of new lumps and relatively smaller and softer lumps during flares. The size of the lumps was not measured by accurate imaging techniques, such as CT scans. However, measurements were done by the hands of the same physician during each clinical visit.

Conclusion

Altogether, our data show the efficacy of treatment with anti-IL-1 agents in a FOP patient, and markedly increased levels of IL-1β during flares suggest a role for IL-1β in the pathogenesis of this disease, although it is too soon to conclude whether FOP may be included under the umbrella of auto-inflammatory syndromes. Anti-IL-1 agents may be effective in ameliorating the natural progression of FOP. Indeed, unlike the “standard” anti-inflammatory agents currently used for prophylaxis, anti-IL-1 agents were efficacious in lowering the rate and extent of heterotopic ossification in our patient. However, further exploration and international experience with other FOP patients are needed.

Abbreviations

BMP: Bone morphogenic protein; FOP: Fibrodysplasia ossificans progressiva; HO: Heterotopic ossification; MAPK: Mitogen-activated protein kinase

Acknowledgements

We thank Faye Schreiber, MS for editing the manuscript.

Authors’ contributions

RH, VM and YU carried out the diagnosis and management of the patient and drafted the manuscript. FDB, GP, and NR performed the laboratory tests, analyzed the results and helped draft the manuscript. All authors read and approved the final manuscript.

Funding

This study was not funded.

Availability of data and materials

The authors do not have permission to share the data.
Ethics approval
This study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.

Consent for publication
The patient’s parents gave informed consent to publish this case anonymously.

Competing interests
The authors declare that they have no competing interests.

Author details
1Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center, 59 Tchernichovsky St., 4428164 Kfar Saba, Israel. 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3Division of Rheumatology, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy.

Received: 25 July 2019 Accepted: 4 December 2019
Published online: 21 December 2019

References
1. Baujat G, Choquet R, Boué S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123.
2. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525–7.
3. Upadhyay J, Xie L, Huang L, et al. Expansion of heterotopic bone in Fibrodysplasia Ossificans Progressiva is Activin A-dependent. J Bone Miner Res. 2017;32:2489–99.
4. Alessi Wolken DM, Idone V, Hatsell SJ, et al. The obligatory role of Activin a in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Bone. 2018;109:210–7.
5. Qi Z, Luan J, Zhou X, et al. Fibrodysplasia ossificans progressiva: basic understanding and experimental models. Intractable Rare Dis Res. 2017;6:242–8.
6. Kaplan FS, Shore EM, Pignolo RJ, et al. (The international clinical consortium on fibrodysplasia ossificans progressiva). The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP. 2011;4:1–100.
7. Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2018. https://doi.org/10.1111/bcp.13823.
8. Gencer-Atalay K, Ozturk EC, Yagci I, et al. Challenges in the treatment of fibrodysplasia ossificans progressiva. Rheumatol Int. 2019;39:569–576.
9. Kaplan FS, Zaskoff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92:686–91.
10. Kaplan FS, Pignolo RJ, Shore EM. Granting immunity to FOP and catching heterotopic ossification in the act. Semin Cell Dev Biol. 2016;49:30–6.
11. Mahy PR, Unist MR. Experimental heterotopic bone formation induced by bone morphogenetic protein and recombinant human interleukin-1β. Clin Orthop Relat Res. 1998;237:236–44.
12. Ferreira E, Porter RM, Wehling N, et al. Inflammatory cytokines induce a unique mineralizing phenotype in mesenchymal stem cells derived from human bone marrow. J Biol Chem. 2013;288(41):29494–505.
13. Ezura Y, Lin X, Hatta A, et al. Interleukin-1β suppresses the transporter genes Ank and Ent1 expression in stromal progenitor cells retaining mineralization. Calcif Tissue Int. 2016;99:199–208.
14. Barquet E, Morales BM, Cain CJ, et al. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight. 2018;3(22):122958.
15. Forsberg JA, Porter BK, Poller EM, et al. Do inflammatory markers portend heterotopic ossification and wound failure in combat wounds? Clin Orthop Relat Res. 2014;472:2845–54.
16. Evans KN, Forsberg JA, Potter BK, et al. Inflammatory cytokine and chemokine expression is associated with heterotopic ossification in high-energy penetrating war injuries. J Orthop Trauma. 2012;26:e204–13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.